Case presentation {#Sec1}
=================

A 40 year-old female with diffuse cutaneous systemic sclerosis (dcSSc) for 3 years was admitted with palpitations (24 hour Holter monitor showed ventricular ectopics). The patient was started on deltiazem 40 mg tid. She developed progressive dyspnea, chocking sensation and cough. The patient started to have abdominal distension, constipation and dysphagia to solids. Arthritis of the knee started to occur with puffiness of the hands and 10 minute morning stiffness and eventually she was unable to close a fist (Her sister has rheumatoid arthritis). She started to feel proximal weakness on going upstairs (grade 4 muscle power). The menstrual cycle became irregular and there would be urgency of urine. Laboratory investigations of the patient are shown in Table [1](#Tab1){ref-type="table"}. The case study conforms to the 1995 Helsinki declaration and the patients gave an informed consent.

There was pitting edema of extremities, peripheral skin tightness, coldness and Raynauds with sluggish peripheral circulation. Skin tightness was increased as reflected by the increased modified Rodnan total skin score (MRSS) which was 37. Multiple purpuric eruptions were present on the legs and of variable sizes (Figure [1](#Fig1){ref-type="fig"}). Skin biopsy histopathology proved small vessel (leucocytoclastic) vasculitis of the purpuric rash. The patient had a positive hepatitis C virus (HCV) test by PCR and positive cryoglobulinemia. The pulmonary function test was consistent with a restrictive pattern with progressive deterioration (FEV1 (58.2%), FVC (64.7%), DLCO (16.9%) and FEV1/FVC (74.5%) compared to the results of her preceding follow-up. Transesophageal echocardiography revealed pulmonary hypertension (RVSP 60 mmHg), EF (63%) with moderate pericardial effusion which were verified by a non-contrast CT chest.Table 1**Laboratory features of the diffuse cutaneous systemic sclerosis patients with pulmonary hypertension and small vessel (cryoglobulinemic) vasculitic rash**Laboratory investigationsHb (g/dl)15.6WBC (×10^3^/mm^3^)5.6Platelets (×10^3^/mm^3^)246CK (U/L)81LDH (U/L)691ESR (mm/1^st^ hr)114Sodium (mmol/L)142Potassium (mmol/L)3.8Calcium (mg/dl)9.2Phosphorus (mg/dl)3.3PT (seconds)17INR1.4PTT (seconds)34.3Triglycerides (mg/dl)102Cholesterol (mg/dl)127Cholesterol/HDL4.4LDL/HDL2.7AST (U/L)19ALT (U/L)7ALP (IU/L)59Creatinine (mg/dl)0.6Urea (mg/dl)9SUA (mg/dl)6.4RFNegativeANAPositive (1:40) homogeneousAnti-ds DNANegativeAnti-Scl-70PositiveAnticentromereNegativeU1RNPnegativeAnti-Ro (U/ml)Positive (28.2)Anti-La (U/ml)Positive (17.9)ANCANegativeCryoglobulinemiaPositiveHCV (PCR)PositiveHb: Hemoglobin, WBC: White blood cells count, CK: creatine kinase, LDH: lactate dehydrogenase, ESR: Erythrocyte sedimentation rate, PT: prothrombin time, INR: Inverse neutralization ratio, PTT: partial thromboplastin time, LDL: low density lipoprotein, HDL: high density lipoprotein, AST: Aspartate transaminase, ALT: alanine transaminase, SUA: serum uric acid, RBF: rheumatoid factor, ANA: antinuclear antibody, ds DNA: double stranded deoxyribonucleic acid, Scl-70: scleroderma 70, U1RNP: Uridine 1 ribonucleoprotein, ANCA: antineutrophil cytoplasmic antibody, HCV: hepatitis C virus.Figure 1**Purpuric skin rash (small vessel vasculitis) in a 40 year old female with diffuse cutaneous systemic sclerosis (dcSSc) and pulmonary arterial hypertension (PAH) before (left) and after (right) treatment with sildenafil.**

The patient was prescribed prednisolone 40 mg/day, warfarin 3 mg/day, furosemide 20 mg with spironolactone 100 mg, verapamil 120 mg/day. In addition, the patient received a daily dose of omeprazole 40 mg, domperidone 10 mg before the main meal, simethicone chew tablets, calcium carbonate 500 mg and colchicines 0.5 mg twice daily for a month. There was slight improvement of the dyspnea and skin rash while all other symptoms persisted. The ESR was reduced from 114 to be 85 mm/1^st^ hr.

One week later it was decided to add *sildenafil* 50 mg/day with a remarkable improvement of the dyspnea and Raynauds' with a reduction of the peripheral edema as well as a significant improvement of the skin tightness as the MRSS became 22. The small vessel vasculitic rash remarkably improved (Figure). The pulmonary function tests significantly improved: FEV1 77%, FVC 79.2%, DLCO 45.2%, FEV1/FVC 88.6. The echocardiography results were enhanced with an EF 73% and a reduction of the pericardial effusion. The RVSP became 34 mmHg with a dramatic improvement of the pulmonary hypertension. The patient significantly improved with a favorable clinical and functional outcome on the regular follow ups for the following year.

Using a selective pulmonary vasodilator as sildenafil contributes to the significant improvement of the clinical conditions and pulmonary hemodynamics which benefits patients with severe pulmonary hypertension resistant to conventional therapy (Catapano-Minotti et al. [@CR2]; Shahin [@CR4]). The pulmonary arterial hypertension associated with connective tissue disease is difficult to manage, and has a poor prognosis. The PDE5 inhibitor 'sildenafil' enhances vasodilatation, has antiproliferative effects, and is effective in the treatment of PAH (Badesch et al. [@CR1]). The vasculopathy associated with SSc is considered noninflammatory, yet frank vasculitis can complicate it posing diagnostic and therapeutic challenges (Kao and Weyand [@CR3]).

We report a very rare association of dcSSc with small vessel cryoglobulinemic vasculitis. It has been reported that cryoglobulinemic vasculitis is rarely encountered in SSc patients (Kao and Weyand [@CR3]). The remarkable improvement in the vasculitic skin lesions in this case after sildenafil is the second report after the described dramatic improvement of small vessel vasculitis in a case with Takayasu arteritis (Uthman and Chaaban [@CR5]). The emerging trends make it necessary to exploit the full therapeutic potential of this class of drugs 'sildenafil' in scleroderma and PAH with other extrapulmonary manifestations.
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